Back to Search
Start Over
Role of the Endothelium in the Vascular Effects of the Thrombin Receptor (Protease-Activated Receptor Type 1) in Humans
- Source :
- Gudmundsdóttir, I J, Lang, N N, Boon, N A, Ludlam, C A, Webb, D J, Fox, K A & Newby, D E 2008, ' Role of the endothelium in the vascular effects of the thrombin receptor (protease-activated receptor type 1) in humans ', Journal of the American College of Cardiology, vol. 51, no. 18, pp. 1749-56 . https://doi.org/10.1016/j.jacc.2007.12.047
- Publication Year :
- 2008
- Publisher :
- Elsevier BV, 2008.
-
Abstract
- The purpose of this study was to determine the role of the endothelium in the vascular actions of protease-activated receptor type 1 (PAR-1) activation in vivo in man.Background Thrombin is central to the pathophysiology of atherothrombosis. Its cellular actions are mediated via PAR-1. Protease-activated receptor type 1 activation causes arterial vasodilation, venoconstriction, platelet activation, and tissue-type plasminogen activator release in man.Methods Dorsal hand vein diameter was measured in 6 healthy volunteers before and after endothelial denudation. Forearm arterial blood flow, plasma fibrinolytic factors, and platelet activation were measured in 24 healthy volunteers during venous occlusion plethysmography. The effects of inhibition of prostacyclin, nitric oxide (NO), and endothelium-derived hyperpolarizing factor on PAR-1 responses were assessed during coadministration of aspirin, the "NO clamp" (L-N-G-monomethyl arginine and sodium nitroprusside), and tetraethylammonium ion, respectively.Results Endothelial denudation did not affect PAR-1-evoked venoconstriction (SFLLRN; 0.05 to 15 nmol/min). Although aspirin had no effect, SFLLRN-induced vasodilation (5 to 50 nmol/min) was attenuated by the NO clamp (p < 0.0001) and tetraethylammonium ion (p < 0.05) and abolished by their combination (p < 0.01). The NO clamp augmented SFLLRN-induced tissue-type plasminogen activator and plasminogen activator inhibitor type 1 antigen (p < 0.0001) release, but tetraethylammonium ion and aspirin had no effect. SFLLRN-induced platelet activation was unaffected by NO or prostacyclin inhibition.Conclusions Acting via PAR-1, thrombin causes contrasting effects in the human vasculature and has a major interaction with the endothelium. This highlights the critical importance of endothelial function during acute arterial injury and intravascular thrombosis, as occurs in cardiovascular events including myocardial infarction and stroke.
- Subjects :
- Adult
Male
medicine.medical_specialty
Endothelium
Pilot Projects
Prostacyclin
030204 cardiovascular system & hematology
Nitric Oxide
Potassium Channels, Calcium-Activated
03 medical and health sciences
0302 clinical medicine
Thrombin
Internal medicine
Thrombin receptor
Humans
Medicine
Receptor, PAR-1
Protease-activated receptor
Platelet activation
Receptor
030304 developmental biology
0303 health sciences
business.industry
Atherosclerosis
Platelet Activation
Epoprostenol
Vasodilation
Endocrinology
medicine.anatomical_structure
Vasoconstriction
Tissue Plasminogen Activator
Female
Receptors, Thrombin
Endothelium, Vascular
Cardiology and Cardiovascular Medicine
business
medicine.drug
Blood vessel
Subjects
Details
- ISSN :
- 07351097
- Volume :
- 51
- Database :
- OpenAIRE
- Journal :
- Journal of the American College of Cardiology
- Accession number :
- edsair.doi.dedup.....368eb4316bfeed32ca62eceedbab488b